Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-08-20, Stock:LLY, The news for the past five days is as follows:
2021-08-13: NEWS1: AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript.
2021-08-16: NEWS1: Eli Lilly Stock Soars To 96 Composite Rating.NEWS2: Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer.NEWS3: Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials.NEWS4: FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps.NEWS5: Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials.
2021-08-17: NEWS1: Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal.NEWS2: Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev.NEWS3: The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business.NEWS4: Eli Lilly creates neuroscience and immunology business units.NEWS5: Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units.
2021-08-18: NEWS1: FDA Approves Eli Lilly's Jardiance For Heart Failure.NEWS2: Is Eli Lilly (LLY) A Smart Long-Term Buy?.NEWS3: US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction.NEWS4: 3 Big Drug/Biotech Outperformers Worth Keeping an Eye On.NEWS5: The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline.
2021-08-19: NEWS1: Lilly's (LLY) Jardiance Gets FDA Approval for Heart Failure.

Answer: Rise